Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NurExone Biologic ( (TSE:NRX) ) has issued an announcement.
NurExone Biologic Inc. announced plans to initiate a Phase 1/2a clinical trial in 2026 for ExoPTEN, an exosome-based therapy for acute spinal cord injuries, marking a significant milestone in regenerative therapies. The announcement, made at the American Spinal Injury Association’s annual meeting, highlights the company’s progress in clinical readiness and the potential impact of ExoPTEN on addressing unmet needs in spinal cord injury treatment, underscoring NurExone’s emergence as an innovator in neuroregeneration.
The most recent analyst rating on (TSE:NRX) stock is a Buy with a C$2.61 price target. To see the full list of analyst forecasts on NurExone Biologic stock, see the TSE:NRX Stock Forecast page.
More about NurExone Biologic
NurExone Biologic Inc. is a biotech company listed on the TSX Venture Exchange, OTCQB, and Frankfurt, focusing on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has shown strong preclinical potential in treating acute spinal cord and optic nerve injuries, targeting multi-billion-dollar markets.
Average Trading Volume: 31,574
Technical Sentiment Signal: Buy
Current Market Cap: C$39.77M
Learn more about NRX stock on TipRanks’ Stock Analysis page.